| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| DBV Technologies S.A. | Viaskin Peanut - (VITESSE) | Peanut allergy | BLA Filing | Ongoing | Transdermal | Immunology |
| Deciphera Pharmaceuticals Inc. | QINLOCK vs sunitinib - (INSIGHT) | Gastrointestinal stromal tumor (GIST) patients with mutations in KIT exon 11 and 17/18 | Phase 3 | oral | Oncology | |
| Deciphera Pharmaceuticals Inc. | Vimseltinib (DCC-3014) - (MOTION) | Tenosynovial Giant Cell tumor | NDA Filing | Ongoing | Oral | Oncology |
| Deciphera Pharmaceuticals Inc. | Vimseltinib (DCC-3014) | Graft versus host disease (cGvHD) | Phase 2 | Enrollment Initiation | Oral | Immunosuppressant |
| Deciphera Pharmaceuticals Inc. | Vimseltinib (DCC-3014) | Graft versus host disease (cGvHD) | Phase 2 | Enrollment Initiation | Oral | Immunosuppressant |
| Deciphera Pharmaceuticals Inc. | QINLOCK (ripretinib) and MEKTOVI (​binimetinib) | Gastrointestinal stromal tumor (GIST) | Phase 2 | oral | Oncology | |
| Deciphera Pharmaceuticals Inc. | QINLOCK (ripretinib) and MEKTOVI (​binimetinib) | Gastrointestinal stromal tumor (GIST) | Phase 2 | oral | Oncology | |
| Deciphera Pharmaceuticals Inc. | QINLOCK (ripretinib) - (INTRIGUE) | Gastrointestinal Stromal Tumors (GIST) - second-line | Phase 3 | Data Released | Oral | Oncology |